Initial vancomycin dosing in pediatric oncology and stem cell transplant patients
Journal of Pediatric Hematology/Oncology, ISSN: 1077-4114, Vol: 31, Issue: 1, Page: 3-7
2009
- 16Citations
- 21Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations16
- Citation Indexes16
- 16
- CrossRef13
- Captures21
- Readers21
- 21
- Mentions1
- News Mentions1
- News1
Most Recent News
Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients
STUDY INFORMATION OFFICIAL TITLE: Evaluation of the Dosing Regimen of Vancomycin in Pediatric Patients CURRENT STATUS: Completed STUDY TYPE: Observational SPONSOR AGENCY:Universitaire Ziekenhuizen LeuvenCLASS:Other TRACKING
Article Description
BACKGROUND: Gram-positive bacteremia is a common infection in pediatric oncology and stem cell transplant (SCT) patients requiring therapy with vancomycin. Optimal dosing of vancomycin in this patient population has not been well established. METHODS: All pediatric oncology and SCT patients receiving vancomycin between October 2006 and March 2007 were included in this study. Therapeutic levels were defined as levels between 10 and 15 mg/dL and low therapeutic levels were between 5 and 9 mg/dL. Information regarding any recent or concurrent nephrotoxic medications was collected. RESULTS: Fifty-six patients received 82 courses of vancomycin during the study period. More patients (53.7%) received vancomycin for empiric therapy and 78% had recent or concurrent use of nephrotoxic medications. Using standardized vancomycin dosing guided by a computerized provider order entry system, there were significantly more patients who were in the subtherapeutic range than the supratherapeutic range (P=0.0023). There were also significantly more patients in the low therapeutic than the therapeutic range (P<0.0001). A small number of courses (3.5%) were associated with supratherapeutic levels. There was no association between the concurrent or recent use of nephrotoxic medications and vancomycin levels. CONCLUSIONS: Pediatric oncology and SCT patients with normal renal function require higher daily vancomycin doses than other pediatric patients. © 2009 by Lippincott Williams & Wilkins.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=59449085779&origin=inward; http://dx.doi.org/10.1097/mph.0b013e31818b3520; http://www.ncbi.nlm.nih.gov/pubmed/19125078; https://journals.lww.com/00043426-200901000-00002; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00043426-200901000-00002; https://dx.doi.org/10.1097/mph.0b013e31818b3520; https://insights.ovid.com/ShowUpgradeBrowserMessage
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know